Edward M. MD Kaye - 15 Mar 2025 Form 4 Insider Report for Stoke Therapeutics, Inc. (STOK)

Role
CEO, Director
Signature
/s/ Jonathan Allan, Attorney-in-Fact
Issuer symbol
STOK
Transactions as of
15 Mar 2025
Net transactions value
$0
Form type
4
Filing time
18 Mar 2025, 16:07:08 UTC
Previous filing
06 Jan 2025
Next filing
20 Mar 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction STOK Common Stock Options Exercise $0 +35,500 +37% $0.000000 132,385 15 Mar 2025 Direct
transaction STOK Common Stock Options Exercise $0 +26,250 +20% $0.000000 158,635 15 Mar 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction STOK Restricted Stock Units Options Exercise $0 -35,500 -33% $0.000000 71,000 15 Mar 2025 Common Stock 35,500 Direct F1, F2
transaction STOK Restricted Stock Units Options Exercise $0 -26,250 -25% $0.000000 78,750 15 Mar 2025 Common Stock 26,250 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement.
F2 The award vested or vests as to 1/4 of the total shares annually beginning March 15, 2024, subject to the reporting person's continued service to the Issuer through each vesting date.
F3 The award vested or vests as to 1/4 of the total award annually beginning on March 15, 2025, subject to the reporting person's continued service to the issuer through each vesting date.